Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes
Liver Cirrhosis, Diabetes
About this trial
This is an interventional treatment trial for Liver Cirrhosis focused on measuring Liver cirrhosis, diabetes, time in range, insulin intensive therapy, new combination therapy
Eligibility Criteria
Inclusion Criteria: Liver cirrhosis Age 18-70 years Patients with elevated blood sugar who meet the diabetes standard or have been treated with hypoglycemic drugs random finger or venous serum blood glucose more than 14 mmol/L Exclusion Criteria: Those unwilling to participate or unable to cooperate; Child-pugh score is greater than 12; Glomerular filtration rate<60ml/min/1.73m2; Patients with cardiac insufficiency; Patients with asymptomatic hypoglycemia; Pregnant patients were excluded; Patients with advanced liver cancer; Blood pressure is less than 90/60mmHg; Chronic liver disease plus acute or subacute liver failure; Patients with drug induced blood glucose disorder, such as glucocorticoids, contraceptives, etc; fingertip oxygen saturation less than 95% without oxygen inhalation; Autoimmune liver cirrhosis is currently taking hormone. Type 1 diabetes. Pancreatogenic diabetes, such as primary hemochromatosis, hepatolenticular degeneration, alcoholic pancreatitis, autoimmune diseases involving the pancreas, etc.
Sites / Locations
- Xiaolong ZhaoRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
group with new combination therapy
group with intensive insulin therapy
The hypoglycemic scheme of the experimental group was that the initial dose of Insulin Degludec and Insulin Aspart was 0.3U/kg multiplied by the patient's weight, plus 5 mg of linagliptin and 0.5 g of metformin three times a day.
group was treated with intensive insulin therapy.The initial total amount of insulin is 0.5U/kg, of which 40% is basal insulin and 20% is aspart insulin before three meals